COYA

Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Retrieved on: 
Friday, April 26, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Doctor of Philosophy, COYA, Reactive oxygen species, Oxidative stress, Houston Methodist Hospital, HMH, Survival, ROS, Death, Disease, Patient, Medulla oblongata, ALS, Diagnosis, Associate, Therapy, Pharmaceutical industry

The data presented highlights the strong predictive value of oxidative stress biomarker (4-HNE) levels with the rate of disease progression and survival in ALS patients from a longitudinal patient registry cohort.

Key Points: 
  • The data presented highlights the strong predictive value of oxidative stress biomarker (4-HNE) levels with the rate of disease progression and survival in ALS patients from a longitudinal patient registry cohort.
  • Reactive oxygen species (ROS) are generated mainly as byproducts of mitochondrial respiration and are tightly controlled by multiple anti-oxidant mechanisms.
  • In neurodegenerative diseases, such as ALS, when the antioxidant system is overwhelmed by overproduction of ROS, oxidative stress occurs.
  • 4-HNE, an abundant and reactive oxygen species, is thought to exert neuronal toxicity ultimately through formation of toxic protein aggregates, as seen in ALS patients.

Coya Therapeutics to Participate in the Mizuho Neuroscience Summit

Retrieved on: 
Monday, April 22, 2024
Health, Neurology, Other Health, General Health, Pharmaceutical, Biotechnology, DRS, COYA, Therapy, Boston Harbor Hotel

More information on the Mizuho Neuroscience Summit can be found at the link below: https://www.mizuhogroup.com/americas/events/2024/mizuho-neuroscience-sum...

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer and Chairman of the Board Howard Berman, Ph.D., and Chief Business Development Officer Arun Swaminathan, Ph.D., will participate in the Mizuho Neuroscience Summit being held May 20 – 21 at the Boston Harbor Hotel.
  • Drs.
  • Berman and Swaminathan will also be available for one-on-one meetings throughout the conference.
  • More information on the Mizuho Neuroscience Summit can be found at the link below: https://www.mizuhogroup.com/americas/events/2024/mizuho-neuroscience-sum...

Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit

Retrieved on: 
Thursday, April 18, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, COYA, Combination, Drug development, D.O, FAPA, Hurdling, Treatment, ALS, Therapy, Medical device

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief Medical Officer Dr. Fred Grossman, D.O., FAPA will participate in the 3rd Annual ALS Drug Development Summit being held May 21 – 23 at the Hyatt Regency in Boston.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief Medical Officer Dr. Fred Grossman, D.O., FAPA will participate in the 3rd Annual ALS Drug Development Summit being held May 21 – 23 at the Hyatt Regency in Boston.
  • On May 21 from 11am – 1pm ET, Dr. Grossman will co-lead a workshop discussion titled, “Navigating the Hurdles of a Combination Therapy Approach & the Need to Demonstrate Efficacy on Top of Existing ALS Treatments” in Workshop B.
  • On May 23 at 1:10pm ET, Dr. Grossman will give a presentation titled, “COYA 302: A Dual Mechanism Biologic Immunotherapy in the Treatment of ALS by Treg Activity to Reduce Inflammation.”
    For more information on the 3rd Annual ALS Drug Development Summit and to register, please visit:

Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Retrieved on: 
Monday, April 8, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diagnosis, Pharmacology, Conference, Survival, Coya, Associate, Patient, Biomarker, COYA, Medulla oblongata, Death, Society, Doctor of Philosophy, Therapy, Poster, FDA

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist, will present updated ALS biomarker data at the upcoming 2nd Annual Johnson Center Symposium in Houston, Texas on April 26, 2024.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist, will present updated ALS biomarker data at the upcoming 2nd Annual Johnson Center Symposium in Houston, Texas on April 26, 2024.
  • The title of the poster is 4-hydroxynonenal (4-HNE) as a Biomarker in ALS.
  • During the Johnson Center Symposium, Dr. Appel will present data correlating 4-HNE levels to bulbar and limb onset ALS.
  • Coya plans to discuss the validation of 4-HNE as a new potential biomarker for ALS and the potential inclusion of 4-HNE as a biomarker in the planned Ph.

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Research, Pharmacology, LD, Survival, Serum, ALS, Science, PD, Houston Methodist Hospital, Patient, Regulatory affairs, Granulocyte-macrophage colony-stimulating factor, FD, GM-CSF, Nebraska Medicine, COYA, University, IPO, Senior, Society, IND, Commerce, Viral disease, Therapy, Frontotemporal dementia, FDA, FTD, Pharmaceutical industry

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2023.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2023.
  • COYA 302 is Coya’s combination of its proprietary LD IL-2 formulation with the immunomodulatory drug CTLA4-Ig.
  • “We believe that we have under-promised and over-delivered in executing on numerous deliverables in 2023 that have brought value to Coya,” commented Howard Berman, Ph.D., Chief Executive Officer of Coya.
  • Net loss was $8.0 million for the year ended December 31, 2023, compared to net loss of $12.2 million for the year ended December 31, 2022.

Coya Therapeutics to Participate in BTIG Fireside Discussion

Retrieved on: 
Tuesday, March 12, 2024
Biotechnology, Pharmaceutical, Health, Neurology, COYA, Survival, Therapy, Pharmaceutical industry

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board and Chief Medical Officer Dr. Fred Grossman will participate in a fireside discussion with BTIG analyst Tom Shrader on Wednesday, March 13, 2024, at 12pm ET.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board and Chief Medical Officer Dr. Fred Grossman will participate in a fireside discussion with BTIG analyst Tom Shrader on Wednesday, March 13, 2024, at 12pm ET.
  • Topics to be discussed include the role of regulatory T cells in treating neurodegenerative diseases, the biomarker (4-HNE) ALS survival data presented today by Dr. Stanley Appel, and Coya’s regulatory pathway for COYA 302, its lead drug candidate that is being explored in Amyotrophic Lateral Sclerosis (ALS), Parkinson’s disease, Frontotemporal disease, and Alzheimer’s disease.
  • Investors interested in attending this event should contact their respective BTIG representative to be granted access.

Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

Retrieved on: 
Tuesday, March 12, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Diagnosis, Pharmacology, LD, Conference, Survival, Serum, Coya, Disease, ALS, Associate, Patient, Biomarker, COYA, ROS, Death, Reactive oxygen species, Society, Therapy, Patent, FDA, Oxidative stress

The data presented highlights the strong predictive value of levels of an oxidative stress biomarker (4-HNE) with the rate of disease progression and survival in 50 ALS patients from a longitudinal patient registry cohort.

Key Points: 
  • The data presented highlights the strong predictive value of levels of an oxidative stress biomarker (4-HNE) with the rate of disease progression and survival in 50 ALS patients from a longitudinal patient registry cohort.
  • In a proof-of-concept study in patients with ALS, the combination of low dose interleukin-2 (LD IL-2) and CTLA-4 Ig appeared to lower 4-HNE and other proinflammatory biomarker levels.
  • Furthermore, Coya has filed patent applications relating to the use of the biomarker in ALS.
  • Data was collected from a previously established biobank at Houston Methodist to monitor and track ALS patient outcomes with biomarkers.

Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference

Retrieved on: 
Wednesday, March 6, 2024
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Central nervous system, Investigational New Drug, Houston Methodist Hospital, Chemokine, Frontotemporal dementia, Messenger, FDA, COYA, Conference, FTD, Therapy, Pathology, Patient, Poster, Role, IND, Pharmaceutical industry

The poster presentation was shared for the first time today at the AD/PD 2024 Conference in Lisbon, Portugal and can be found here .

Key Points: 
  • The poster presentation was shared for the first time today at the AD/PD 2024 Conference in Lisbon, Portugal and can be found here .
  • We intend to file an Investigational New Drug (IND) application with the FDA for COYA 302 in FTD later this year and initiate a Ph.
  • 2 trial in FTD patients shortly thereafter,” stated Fred Grossman, Chief Medical Officer at Coya Therapeutics.
  • In addition, several inflammation transcripts in monocyte genes known to be involved in neuroinflammatory signaling pathways were dysregulated in FTD, compared to controls.

Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference

Retrieved on: 
Thursday, February 29, 2024
Research, Neurology, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Inflammation, COYA, Conference, FTD, Therapy, Pathology, Patient, Poster, Role, IND, Pharmaceutical industry

The AD/PD 2024 Conference will be held March 5-9, 2024 in Lisbon, Portugal.

Key Points: 
  • The AD/PD 2024 Conference will be held March 5-9, 2024 in Lisbon, Portugal.
  • The poster, titled “Deciphering the Role of the Peripheral Immune System in the Pathology of Frontotemporal Dementia,” will be presented on March 6 and 7.
  • The work was funded by a grant from the Houston Methodist Clinical Scholar Award Program.
  • This presentation will highlight the complexity of neuroinflammatory pathways, providing the rationale for our planned IND filing for COYA 302, our combination therapeutic candidate, in FTD patients in 4Q24.”

Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference

Retrieved on: 
Thursday, February 22, 2024
Research, Neurology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, ALS, FDA, COYA, Conference, Therapy, Pharmacology, Patient, Survival, Oxidative stress, Mutation, NFL, Neurodegenerative disease, Amyotrophy

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, will present data on its novel oxidative stress biomarker candidate from a large cohort of Amyotrophic Lateral Sclerosis (ALS) patients at the upcoming Society of Neuroimmune Pharmacology Conference being held on March 10-13, 2024 in Charleston, SC.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, will present data on its novel oxidative stress biomarker candidate from a large cohort of Amyotrophic Lateral Sclerosis (ALS) patients at the upcoming Society of Neuroimmune Pharmacology Conference being held on March 10-13, 2024 in Charleston, SC.
  • Dr. Appel’s presentation will be on Tuesday, March 12th, 2024, and is titled Immunomodulatory Therapy in Neurodegenerative Disease: Lessons from ALS.
  • Dr. Fred Grossman, Coya’s Chief Medical Officer, stated: “Neurofilament Light Chain (NFL), despite its lack of specificity for ALS, is currently the only robust and validated biomarker used for diagnostic and prognostic performance in symptomatic ALS patients.
  • We believe that our preliminary novel biomarker data may facilitate new opportunities to better predict patient survival, monitor disease progression, and track efficacy of therapies and will be an important part of the analysis in the upcoming Ph.